SubsidieMeestersBringing newborn care home: An integral mHealth solution for neonatal jaundice management.
Picterus is creating a digital platform for at-home neonatal jaundice screening, empowering families to monitor conditions and streamline healthcare referrals, improving outcomes and resource efficiency.
Projectdetails
Introduction
Neonatal jaundice (NNJ) affects 60%-80% of newborns worldwide (84-112 million/year). Ten percent will develop severe jaundice (SNJ), which can cause permanent brain damage or even death. This results in approximately 114,000 newborns dying each year, with 75,000 suffering severe long-term neurological impairments.
Current Challenges
A fast, point-of-care, affordable method for NNJ screening and monitoring in the first 2 weeks of life is crucial. However, current methods are insufficient, including:
- Visual assessment
- Transcutaneous device
- Blood test
Health systems face increasing pressure on their resources. It is imperative to develop more sustainable models of care and empower patients and their families.
Project Overview
Picterus is developing the first digital platform to enable NNJ screening by parents and caregivers at home. This platform will facilitate timely referrals to healthcare services.
Features of the Platform
Our recommendation tool will allow families to:
- Monitor NNJ at home with their smartphones.
- Enable healthcare workers to efficiently manage a greater number of families by avoiding unnecessary visits.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.499.999 |
| Totale projectbegroting | € 3.938.916 |
Tijdlijn
| Startdatum | 1-9-2023 |
| Einddatum | 31-8-2025 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- PICTERUS ASpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
A new cardioprotective drug for acute treatment of myocardial infarctionResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Clear, scalable and scientific framework to measure terrestrial biodiversity3Bee leverages IoT, wildlife monitoring, and satellite data to measure and regenerate biodiversity, generating certified Biodiversity Credits for corporations to enhance ESG reporting and brand value. | EIC Accelerator | € 2.252.714 | 2024 | Details |
Novel and Scalable microbial products for REgenerative agricultureN-Spire aims to revolutionize agriculture by creating a sustainable bioactive fertilizer through innovative manufacturing techniques, enhancing soil health and reducing chemical dependency. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Quantum-based Randomness Processing Units (RPUs) for High-Performance Computation and Data SecurityQuside's Randomness Processing Unit (RPU) accelerates stochastic HPC and PQ cryptography by optimizing random workloads, enhancing efficiency and performance across various sectors. | EIC Accelerator | € 2.499.999 | 2024 | Details |
A new cardioprotective drug for acute treatment of myocardial infarction
ResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies.
Clear, scalable and scientific framework to measure terrestrial biodiversity
3Bee leverages IoT, wildlife monitoring, and satellite data to measure and regenerate biodiversity, generating certified Biodiversity Credits for corporations to enhance ESG reporting and brand value.
Novel and Scalable microbial products for REgenerative agriculture
N-Spire aims to revolutionize agriculture by creating a sustainable bioactive fertilizer through innovative manufacturing techniques, enhancing soil health and reducing chemical dependency.
Quantum-based Randomness Processing Units (RPUs) for High-Performance Computation and Data Security
Quside's Randomness Processing Unit (RPU) accelerates stochastic HPC and PQ cryptography by optimizing random workloads, enhancing efficiency and performance across various sectors.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Preterm Brain-Oxygenation and Metabolic EU-Sensing: Feed the BrainPrometeus aims to personalize nutrition for premature neonates in NICUs through real-time adjustments of glucose and nutrients based on brain needs, reducing the risk of neurodevelopmental disabilities. | EIC Pathfinder | € 3.554.156 | 2023 | Details |
Early Moves at Home: a deployable and scalable serviceHet project richt zich op het vroegtijdig diagnosticeren van ontwikkelingsstoornissen bij hoog-risico pasgeborenen thuis, om de ontwikkeling van kinderen te verbeteren en zorgkosten te verlagen. | MIT R&D Samenwerking | € 200.000 | 2022 | Details |
Thuisbehandeling en monitoring van geelzucht bij pas- en vroeggeborenen: User flowHet project richt zich op het ontwikkelen van effectieve behandelingen voor geelzucht bij pasgeborenen, met speciale aandacht voor vroeggeborenen om neurologische schade te voorkomen. | MIT Haalbaarheid | € 20.000 | 2022 | Details |
Innovatief patiënt monitoringsysteem voor sepsis in baby’s en jonge kinderen in lage- en middeninkomenslanden.GOAL 3 ontwikkelt een betaalbaar patiëntmonitoringsysteem voor vroegtijdige detectie van septische shock bij baby’s in LMIL, gericht op het verbeteren van zorgcapaciteiten en -resultaten. | MIT Haalbaarheid | € 20.000 | 2020 | Details |
Preterm Brain-Oxygenation and Metabolic EU-Sensing: Feed the Brain
Prometeus aims to personalize nutrition for premature neonates in NICUs through real-time adjustments of glucose and nutrients based on brain needs, reducing the risk of neurodevelopmental disabilities.
Early Moves at Home: a deployable and scalable service
Het project richt zich op het vroegtijdig diagnosticeren van ontwikkelingsstoornissen bij hoog-risico pasgeborenen thuis, om de ontwikkeling van kinderen te verbeteren en zorgkosten te verlagen.
Thuisbehandeling en monitoring van geelzucht bij pas- en vroeggeborenen: User flow
Het project richt zich op het ontwikkelen van effectieve behandelingen voor geelzucht bij pasgeborenen, met speciale aandacht voor vroeggeborenen om neurologische schade te voorkomen.
Innovatief patiënt monitoringsysteem voor sepsis in baby’s en jonge kinderen in lage- en middeninkomenslanden.
GOAL 3 ontwikkelt een betaalbaar patiëntmonitoringsysteem voor vroegtijdige detectie van septische shock bij baby’s in LMIL, gericht op het verbeteren van zorgcapaciteiten en -resultaten.